March 14th, 2017
Louisville, KY – March XX, 2017 — Eurofins Genomics, the pioneer of high-throughput oligonucleotide synthesis, announced the U.S. commercial launch of a unique DNA synthesis service based on the company’s revolutionary next-generation synthesis platform. The service, which is designed to supply small quantities of high-quality oligos for use in molecular biology and synthetic biology, among other applications, allows users to receive high-fidelity, QC-verified oligos for low cost and with industry-leading turnaround.
Standard approaches to synthesizing oligonucleotides—commonly used as primers for PCR, qPCR, and next-generation sequencing-based workflows—produce much more DNA than scientists need, forcing them to pay for excess material that will never be used. The new Eurofins Genomics synthesis platform was engineered for scalability, producing both small synthesis scale (down to 0.5 nanomoles) to very large orders of DNA. By allowing scientists to choose how much DNA to buy, this service will reduce costs and enable users to perform more experiments on the same budget.
Eurofins Genomics has made a series of recent improvements to its oligo synthesis services. In the U.S. and Canada, orders for oligos meeting the specified scale, length and purification criteria and placed as late as 5:00 p.m. are eligible for same-day synthesis and overnight shipping for no additional surcharge. The company also launched EXTREmer oligonucleotides, extremely long oligos produced at low yield and with low error rates, which are ideal for synthetic biology and CRISPR experiments. In addition, the company has expanded the hours of operation for its service lab to include Sundays, so is now running seven days a week and virtually around the clock to ensure reliability for customers.
“By completely reimagining the synthesis process, including applying tenants of aerospace engineering, we have created a new platform that will help users accelerate their science while ensuring the quality and reliability of their results,” said Martin Kunz, President, Eurofins Genomics US. “We have been very encouraged by feedback about our next-generation synthesis technology from customers in our beta program and are pleased to expand its availability to more scientists in the U.S.”
© Eurofins MWG Operon, LLC. A Eurofins Genomics Company